Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications

Jasper Therapeutics, Inc. ((JSPR)) announced an update on their ongoing clinical study.

Jasper Therapeutics, Inc. is conducting a Phase 2, open-label extension study titled ‘Open-Label Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Chronic Urticaria.’ The study aims to assess the long-term safety, clinical activity, and pharmacodynamics of briquilimab in participants who were previously part of a Jasper-sponsored chronic urticaria trial. This research is significant as it explores extended safety and efficacy, crucial for potential long-term treatment options for chronic urticaria.

The intervention being tested is briquilimab, an experimental drug administered via subcutaneous injection. Its purpose is to treat chronic urticaria by potentially offering a long-term therapeutic solution.

The study follows an interventional design with a single-group assignment. There is no allocation or masking involved, and the primary purpose is treatment. This straightforward design allows for a clear evaluation of briquilimab’s effects over an extended period.

The study began on November 20, 2024, with the last update submitted on July 16, 2025. These dates are crucial as they mark the study’s progress and the latest information available, indicating ongoing data collection and analysis.

The update on this study could positively impact Jasper Therapeutics’ stock performance and investor sentiment, as successful long-term results may enhance the company’s market position in the chronic urticaria treatment landscape. Investors should also consider the competitive environment and advancements by other companies in similar therapeutic areas.

The study is ongoing, and further details are available on the ClinicalTrials portal.